In order to demonstrate the effects of antiangiogenic therapies, it is necessary to be able to stain and measure newly formed blood vessels.
By measuring the MicroVessel Density (MVD) using our image analysis software we can identify changes to the size/number of stained blood vessels following therapy within given samples.
It is important to be able to demonstrate the presence of a particular target in a disease process. Using optimised IHC and ISH assays Histologix can detect the presence of, and is able to quantify the levels of target present within cell lines, patient tissue or xenografts.
Target distribution is also useful data to generate as part of the validation process. Using IHC or ISH it will be possible to mine expression data from archive material of tumour populations. This will provide useful information when identifying therapy target or choosing the most likely antibody clones to develop as prognostic/predictive markers. The use of tissue microarrays (TMA’s) from specific disease types is another useful way to obtain relevant data from many samples which can be combined with the necessary clinical history and patient follow-up data.
Abnormal cell proliferation is fundamental in tumourigenesis. Being able to identify and measure cell proliferation in pre and post therapeutic tissues is an important endpoint in determining drug therapy efficacy and in turn may be linked to apoptosis.
A number of proliferative markers used for this purpose have been optimised by Histologix, along with quantitation using the Halo™ image analysis software will accurately and consistently measure proliferative index (% positive cells from a total of all cells).
With a number of the original biotherapeutic molecules soon to be coming out of license there is a significant amount of interest in demonstrating similarities to generic versions of these drugs, eg. Rituximab, Avastin and Herceptin.
One of the many ways to demonstrate similarities between the generic and original versions is to generate xenografts from the relevant over-expressing tumour cell lines in SCID or Nude mice and to treat these with the relevant compounds using IHC/ISH to identify, quantify and compare data using Halo™ image analysis software.
Histologix provides the Pharmaceutical and Biotechnology industry with specialist pathology services to assist drug development programmes ranging from Discovery, regulatory preclinical safety testing through to clinical trials and include human tissue sourcing, histology, medical and veterinary histopathology, immunohistochemistry, digital pathology and image analysis. These are technologies that have been developed with to meet current and future requirements of targeted therapy.
Through inward investment the services provided by Histologix Ltd use a range of highly sophisticated technologies and platforms aimed at standardising the various processes involved in order to achieve data generation that is consistent, accurate and reproducible and will assist our clients in the development of their drug programmes.
Histologix is a privately owned contract research organisation that provides specialist pathology services for the Pharmaceutical and Biotechnology industry. Set up in 2005 by industry specialists, Histologix is a GLP/GCP accredited, HTA-licenced company with an extensive and impressive track record of successfully delivering a range of IHC/ISH assays to large and small Pharma/Biotechnology companies and is a preferred supplier of these services to a number of companies.
Find out which conference Histologix is exhibiting at, updated news issues and current vacancies.